Free Trial

Sensei Biotherapeutics (SNSE) Stock Forecast & Price Target

Sensei Biotherapeutics logo
$0.45 -0.01 (-1.86%)
(As of 11/15/2024 08:55 PM ET)

Sensei Biotherapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
3

Based on 3 Wall Street analysts who have issued ratings for Sensei Biotherapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for SNSE.

Consensus Price Target

$4.33
855.53% Upside
According to the 3 analysts' twelve-month price targets for Sensei Biotherapeutics, the average price target is $4.33. The highest price target for SNSE is $5.00, while the lowest price target for SNSE is $4.00. The average price target represents a forecasted upside of 855.53% from the current price of $0.45.

SNSE Analyst Ratings Over Time

TypeCurrent Forecast
11/19/23 to 11/18/24
1 Month Ago
10/20/23 to 10/19/24
3 Months Ago
8/21/23 to 8/20/24
1 Year Ago
11/19/22 to 11/19/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.33$4.33$4.33N/A
Forecasted Upside855.53% Upside948.98% Upside594.00% UpsideN/A
Consensus Rating
Buy
Buy
Buy
Buy
The Harvard Business School proved his stock picking system works (Ad)

If you missed our last email, I hope you see this one. You see, this Tuesday afternoon we’re sitting down with the #1 ranked stock picker in North America. A man who’s beat out 16,000 stock market professionals on Sum Zero to claim the top spot… He was amongst the first to recommend many of today’s most dominant companies, including both Apple and Nvidia. And for the first time on a large scale, he’s going to share the stock rating system that made it all possible… Not only has this system been proven to generate significant alpha by The Harvard Business School… It also earned a patent from the US government… The technology behind this system is out of this world, and our #1 stock picker has agreed to let us test a number of stocks against it.

Follow this link here we’ll add you to the guest list.

SNSE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SNSE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sensei Biotherapeutics Stock vs. The Competition

TypeSensei BiotherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside855.53% Upside28,497.56% Upside9.87% Upside
News Sentiment Rating
Positive News

See Recent SNSE News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/7/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00+515.38%
6/3/2024Citigroup
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$4.00+476.36%
5/24/2024Stephens
4 of 5 stars
S. Loganathan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$5.00 ➝ $5.00+589.84%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:48 AM ET.


SNSE Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Sensei Biotherapeutics is $4.33, with a high forecast of $5.00 and a low forecast of $4.00.

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNSE shares.

According to analysts, Sensei Biotherapeutics's stock has a predicted upside of 855.53% based on their 12-month stock forecasts.

Analysts like Sensei Biotherapeutics more than other "medical" companies. The consensus rating for Sensei Biotherapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SNSE compares to other companies.


This page (NASDAQ:SNSE) was last updated on 11/18/2024 by MarketBeat.com Staff
From Our Partners